FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 09/2023”. The Monitor is a month-to-month revealed overview of enterprise capital traits within the European Life Sciences sector.
As of the tip of September 2023 we establish the next present VC traits in Europe:
- In 2023, general Life Sciences funding has reached EUR 6,494m
- Biotech obtained 45% of the entire funding quantity (-1% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- CMR Surgical (United Kingdom) has the best transaction quantity of EUR 142m in September, adopted by Rejuveron (Switzerland) EUR 69m and Corteria Prescription drugs (France) EUR 65m
- The European Innovation Council Fund (Belgium) dominates the Prime 5 Traders (by deal quantity), adopted by Revival Healthcare Capital (United States) and Gilde Healthcare Companions (Netherlands)
- Prime 5 Offers exceed EUR 130m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.